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Re: Final decision: Major revision 
No. BC-D-13-00765 
Title: Long noncoding RNA are aberrantly expressed in vivo in the cystic fibrosis bronchial epithelium 
The International Journal of Biochemistry & Cell Biology 
 
21st February, 2104. 
 
Dear Jean-Michel, 
We would like to thank you and the reviewers for assessing our manuscript entitled "Long noncoding 
RNA are aberrantly expressed in vivo in the cystic fibrosis bronchial epithelium". Your comments 
were very helpful to us in improving the manuscript. We have addressed all of your comments and 
performed additional validation studies in more clinical samples, and expanded figure 1; we provide 
a point-by-point response below. We hope that our work is now acceptable for publication in The 
International Journal of Biochemistry & Cell Biology. 
Kind regards, 
Catherine   
 
 
Reviewers' comments: 
Reviewer #1: In this work entitled "Long noncoding RNA are aberrantly expressed in vivo in the cystic 
fibrosis bronchial epithelium" by McKiernan et al., the authors describe a significantly altered lncRNA 
and mRNA expression profile in cystic fibrosis (CF) bronchial cells in vivo. Authors profile the 
expression of lncRNA and mRNA in airway epithelial cells obtained from endobronchial brushings 
from 3 CF patients and 3 individuals without CF, by microarray hybridization. Of 30,586 lncRNAs 
spotted on the microarray, 1,063 were found differentially expressed in CF samples vs. non-CF 
samples. Similarly, of 26,109 mRNAs present on the microarray, 720 were differentially expressed 
between CF and non-CF samples. An enrichment analysis of GO terms indicates that mRNAs up-
regulated in CF are related to inflammation and Toll-like receptor signalling and mRNAs down-
regulated in CF are related to regulation of metabolism. Four differentially expressed lncRNAs were 
further analyzed by qRT-PCR in independent bronchial brushing samples (3 CF patients and 3 non-
CF). The dysregulation of only two lncRNAs (XIST and HOTAIR) was validated, while qRT-PCR failed 
confirming the dysregulation of the two other lncRNAs (MALAT1 and RP11_59E19.4). A fifth lncRNA, 
antisense to TLR8 mRNA (TLR8-AS1), was down-regulated in the microarray experiment and 
reportedly validated by qRT-PCR on 2 additional independent samples from each group (although 
Response to Reviewers
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data are not shown for the latter qRT-PCR experiments). Interestingly, TLR8 mRNA had a behaviour 
specular to TLR8-AS1 in microarray and qRT-PCR analyses (although data are not shown for qRT-
PCR). 
Overall, this is a straightforward and interesting paper, that would however greatly benefit from 
further data analysis, presentation and argumentation. 
 
1) A table listing the 1,063 differentially expressed lncRNAs, their fold change and p-values, should 
be provided (even as Supplementary material) to make these data accessible to the scientific 
community. 
AUTHOR RESPONSE: As requested we now include this information as Supplementary Table 1. 
 
2) A table listing the 720 differentially expressed mRNAs, their fold change and p-values, should be 
provided (even as Supplementary material) to make these data accessible to the scientific 
community. 
AUTHOR RESPONSE: As requested we now include this information as Supplementary Table 2. 
 
3) Microarray data should be made available to other scientists by depositing them in repositories 
such as GEO or ArrayExpress, and mentioning the accession number in the manuscript. 
AUTHOR RESPONSE: As requested we have deposited the data in GEO and mention the accession 
no. in the manuscript as follows: 
‘Microarray data from this study has been archived to the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo, accession number GSE55146).’ 
The following link has been created to allow review of record GSE55146 while it remains in private 
status: 
 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=mnyzuwwivpklvwh&acc=GSE55146 
 
 
4) It is not clear if technical replicates were performed in the qRT-PCR analyses, and how many. This 
is common practice in the field, and the issue should be detailed in Results and in Methods sections 
and in Figure 2 legend. 
AUTHOR RESPONSE: Technical replicates were not performed due to scarcity of sample. This is 
now stated in the validation section of the methods ‘Technical replicates were only performed on 
reference gene PCR due to scarcity of sample’ and is also stated in the figure legends. 
 
5) On page 9 authors state "Validation by qRT-PCR in additional independent clinical samples failed 
3 
 
3 
 
to confirm this expression pattern for MALAT1 and RP11_59E19.4". Why did authors not validate the 
microarray experiments by performing qRT-PCR on the SAME samples they used in microarray 
experiments? If that was for lack of material, which is understandable due to the scarcity of the 
sample, they should state it. However, with such an experimental design, it is not possible to 
understand whether the difference observed between microarray experiments and qRT-PCR 
experiments is due to the different methodology used or the difference in sample nature. 
AUTHOR RESPONSE: As the reviewer correctly surmises the reason that validations were not 
performed on the original samples was due to a lack of material. We state this in the validation 
section in the methods as follows ‘These validations could not be performed on the original 
samples due to a lack of material’. 
Also we now have performed additional validations on a total of n=7 CF and n=9 non-CF samples. 
This more reliable data allows us to make better conclusions and on this basis we now show 
validations for TL8 and XIST, show no validation for Hotair or Malat1 (and have altered the text 
accordingly), and have removed the data related to RP11_59E19.4. 
 
6) Authors should consider whether the discordance between microarray experiments and qRT-PCR 
experiments might be due to the use of GAPDH as a reference gene in qRT-PCR. In fact, authors 
should evaluate if GAPDH is a suitable reference gene in their experimental setting (i.e. if its mRNA 
levels might change do to cystic fibrosis or related processes in bronchial brushing samples), and 
elaborate on this in the discussion section, citing the following literature. Possibly, authors should 
use more reference genes in their qRT-PCR analyses. The majority of studies published on qRT-PCR 
in lung setting uses a general approach of normalisation against GAPDH or ACTB (beta-actin). 
However, these "traditional" reference genes have been already found unsuitable for normalising of 
mRNA levels in asthmatic airways (Glare EM, Divjak M, Bailey MJ, Walers EH 2002 Thorax 57:765-70) 
and also for expression studies employing bronchoalveolar macrophages (Ishii T, Wallace AM, Zhang 
X, Gosselink J, Abboud RT, English JC, Pare PD, Sandford AJ Eur Respir J 2006, 27:300-6) and 
bronchoalveolar cells (Kriegova E et al., BMC Mol Biol 2008 Jul 31;9:69. doi: 10.1186/1471-2199-9-
69). A recent study aimed at identifying reference genes with the most stable mRNA expression in 
the bronchoalveolar lavage cells of horses with Equine Inflammatory Airway Disease (IAD) indicated 
that the number of genes required for optimal normalization was four and included GAPDH, SDHA, 
HPRT and RPL32 (Beekman et al., BMC Mol Biol 2011 Jan 28;12:5. doi: 10.1186/1471-2199-12-5). 
AUTHOR RESPONSE: As requested we have evaluated the usefulness of GAPDH as a reference 
gene. From the mRNA data we can confirm that expression of GAPDH was not significantly 
different between the CF and non-CF bronchial brushing samples tested. We have also performed 
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qRT-PCR using a second reference gene (β-actin) which was unchanged between the samples 
tested, and which we have used previously (Oglesby et al. J Immunol 2013 and 2013). We state 
this in the validation section of the methods as follows: ‘Amplification was performed using the 
LightCycler 480 PCR system (Roche) with the expression of target genes relative to the reference 
genes GAPDH and ACTB, determined using the 2(−ΔΔCt) method.’ 
In the discussion we refer to the potential limitation of using these 2 references genes and cite the 
papers suggested by the reviewer as follows: 
‘As regards qRT-PCR, ‘traditional’ reference genes such as GAPDH and ACTB have previously been 
found to be unsuitable for normalisation of mRNA levels in the airways of asthmatics (Glare et al., 
2002), for gene expression studies employing alveolar macrophages from people with chronic 
obstructive pulmonary disease (Ishii et al., 2006b) and in bronchoalveolar cells from patients with 
other pulmonary diseases (Kriegova et al., 2008). A study to determine the reference genes with 
the most stable mRNA expression in bronchoalveolar cells from horses with inflammatory airway 
disease identified an optimal four gene reference panel (Beekman et al., 2011).  Due to a lack of 
biological material at our disposal, we utilised a two gene normalisation approach using GAPDH 
and ACTB in combination, having validated that there is no significant difference in expression of 
either gene between bronchial epithelial cells subjects from CF or control groups.’ 
 
7) Several CF transcriptomics studies have employed microarrays to measure differences in global 
gene expression caused by the F508del mutation in isogenic bronchial cells (Virella-Lowell I, Herlihy 
J, Liu B, Lopez C, Cruz P, Muller C, Baker H, Flotte T Mol Ther 2004, 10:562-573), primary cultures of 
tracheal and bronchial cells (Zabner J, Scheetz TE, Almabrazi HG, Casavant TL, Huang J, Keshavjee S, 
McCray PB Am J Physiol Lung Cell Mol Physiol 2005, 289:L545-L553), native nasal epithelial and 
bronchial cells (Wright JM, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JG, Guggino WB, Boyle MP Am J 
Respir Cell Mol Biol 2006, 35:327-336; Ogilvie V, Passmore M, Hyndman L, Jones L, Stevenson B, 
Wilson A, Davidson H, Kitchen RR, Gray RD, Shah P: Genomics 2011, 98:327-336)  and immortalized 
foetal tracheal cell lines (Verhaeghe C, Remouchamps C, Hennuy B, Vanderplasschen A, Chariot A, 
Tabruyn S, Oury C, Bours V Biochem Pharmacol 2007, 73:1982-1994).  A meta-analysis of four 
independent microarray studies (Hampton T, Stanton B Am J Physiol Lung Cell Mol Physiol 2010, 
298:L473-L482) concluded that very few individual genes were among the highest regulated in more 
than two of the four studies, and that there was little evidence associating induction of pro-
inflammatory pathways with the presence of F508del-CFTR. Recently, a small-scale microarray study 
of differential gene expression in human native nasal epithelial cells from five F508del-homozygous 
CF patients vs. five control individuals yielded a small molecular CF signature (Clarke LA, Sousa L, 
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Barreto C, Amaral MD 2013 Respir Res 14:38. doi:10.1186/1465-9921-14-38). Authors should detail 
and comment how their coding mRNA microarray data compare with the aforementioned papers. 
AUTHOR RESPONSE: We thank the reviewer for suggesting we compare our data to these studies. 
The revised discussion now details and comments on how our study compares with these previous 
reports as follows: 
‘Other studies have profiled mRNA expression within the context of CF.  At least three studies 
have profiled mRNA expression in the CF nasal epithelium (Clarke et al., 2013, Ogilvie et al., 2011, 
Wright et al., 2006).  Worth noting is the fact that all of these studies identified different groups of 
differentially expressed genes, with few consistently altered in cystic fibrosis.  Differences 
between studies may be partly explained by different experimental procedures employed.  These 
differences include genotype of the cells used, statistical or normalisation approaches and tissue 
type; such as bronchial and nasal brushings (Clarke et al., 2013, Ogilvie et al., 2011, Wright et al., 
2006), isogenic bronchial cells (Virella-Lowell et al., 2000), primary tracheal and bronchial cell 
cultures (Zabner et al., 2005) and fetal tracheal cells (Verhaeghe et al., 2007).  It remains to be 
determined what direct contribution mutant CFTR makes to an altered CF transcriptome, and it is 
highly likely that other factors such as infection and inflammation are major contributors to this 
altered expression of both lncRNAs and protein coding transcripts.’ 
 
8) On page 10 authors state "Many of these processes which are over-represented in CF bronchial 
brushings are related to inflammation and Toll-like receptor signaling (Table 4). In contrast, many of 
these processes which are UNDER-represented in CF bronchial brushings are involved in regulation 
of metabolism (Table 5)." However, in contrast with the text, Table 4 legend mentions "up-regulated 
processes" and Table 5 legend mentions "down-regulated processes" which are all likely to be OVER-
represented in CF vs. non-CF samples (as enrichment scores are positive). Authors should take better 
care in explaining how the enrichment analysis was done and what it shows. Since the microarray 
contained only 29,109 protein coding transcripts how were these chosen among the human 
genome? Were they somehow related to inflammation and Toll-like receptor signalling? What was 
used as a background gene list to analyse enrichment? The whole human genome? The list of the 
29,109 genes present on the array? 
 
AUTHOR RESPONSE: We apologise for the mis-use of the terms and have corrected the text 
accordingly.  
We have elaborated on how the enrichment analysis was done and what it shows in the methods 
and results as follows: 
6 
 
6 
 
‘Pathway analysis and gene ontology (GO) analysis were applied to determine the potential roles 
that the differentially expressed mRNAs played in biological pathways or GO terms.  The GO 
project provides a controlled vocabulary to describe gene and gene product attributes in any 
organism (http://www.geneontology.org). The ontology covers three domains: biological process, 
cellular component and molecular function. Fisher’s exact test is used to find if there is more 
overlap between the differentially expressed gene list and the GO annotation list (Ashburner et al. 
2000) than would be expected by chance. The p-value denotes the significance of GO terms 
enrichment in the differentially expressed gene list.’ 
‘Gene ontology (GO) analysis is a functional analysis associating differentially expressed mRNAs 
with GO categories. The GO categories are derived from the Gene Ontology Project 
(http://www.geneontology.org), which comprise three structured networks of defined terms that 
describe gene product attributes. GO analysis of the differentially expressed mRNAs in this study 
identified numerous biological processes with significantly altered expression of gene products 
involved.’ 
……and describe how the ~29,000 genes were chosen as follows: 
‘Our microarray enabled the expression analysis of ~26,109 protein coding transcripts, broadly 
covering the ~20,600 protein coding genes estimated by GENCODE’ 
  
9) The data related to TLR8 mRNA and TLR8-AS1 qRT-PCR (presently data not shown) should be 
shown in an additional figure. 
AUTHOR RESPONSE: As requested we now include additional data in Figure 4. Having performed 
validations on the additional samples, the TLR8 validation remained intact.  Technically, validation 
of TLR8-AS1 proved problematic due to its very low expression levels, therefore we analysed the 
PCR products by agarose gel. We state this in the results as follows: 
‘TLR8 mRNA expression was confirmed to be up-regulated in the CF group.  TLR8-AS1 lncRNA 
expression was identified in three out of nine additional independent non-CF samples and only 
one of seven independent CF brushing samples, as determined by PCR followed by agarose gel 
electrophoresis (data not shown).’   
We have not added the gel image to the manuscript however can supply it as supplementary data 
if necessary. We have tempered the discussion to reflect these additional experiments as follows: 
‘Here, microarray profiling data suggested that the TLR8 natural antisense lncRNA, the 1349 bp 
TLR8-AS1 transcript, is down-regulated in CF bronchial epithelium. PCR analysis detected low level 
expression in three out of nine non-CF control and in only one out of seven CF bronchial epithelial 
samples.’ 
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10) Were the non-CF controls possibly having other (lung) pathologies or they can be considered 
healthy subjects? Please mention in the methods section. 
AUTHOR RESPONSE: In the methods we now mention that ‘Non-CF control individuals were 
undergoing exploratory bronchoscopy in the investigation into idiopathic pulmonary disease’.  
 
11) The section describing the microarray data analysis should be more detailed: what was used to 
normalise the data? a gene? a set of reference genes? the mean of the feature intensity values on 
the array? This issue has a certain relevance, also in connection with the reference gene used in qRT-
PCR experiments, as different references make the obtained CF profile different. 
AUTHOR RESPONSE: Quantile normalisation was used, we now state this in the methods as 
follows: ‘After quantile normalization of the raw data; a transformation to make the distribution 
of probe intensities identical for all arrays was performed, data was filtered to remove transcripts 
with unreliable expression measurements (transcripts that at least 1 out of 6 samples have flags in 
‘present’ or ‘marginal’ were chosen for further analysis), lncRNAs and mRNAs with expression 
above a set threshold were chosen for further analysis.’ 
 
12) On page 10 line 11, and page 14 line 8: is reference Oglesby, Bray, 2010 correct or should be 
Oglesby et al. 2013? I believe this latter reference (J. Immunol 190:3354) is missing from the 
References section. 
13) Page 11: are (Johnsson et al., 2013) and (Johnsson, Lipovich, 2013) the same reference? 
14) Page 28, reference Johnsson et al., issue and page numbers are missing 
AUTHOR RESPONSE:  We apologise for the errors in referencing. We have corrected these 
mistakes. 
 
15) Page 11: lung adenocarcinomas are the most frequent subtype of nonsmall cell lung cancer; Feng 
et al., 2012 characterise the expression of MALAT1 in laryngeal squamous cell carcinoma, NOT in 
lung cancer. Therefore the sentence should be rephrased: "Most recent studies have examined the 
expression of lncRNA in various non small cell lung cancers (Liu et al., 2013; Lu et al., 2013, Yang et 
al., 2013)." and Feng et al., 2012 should be removed from references. 
AUTHOR RESPONSE: As requested we have rephrased the text accordingly. 
 
16) In the discussion authors comment on the fact that the expression of XIST, a gene located on 
chromosome X, is detectable also in male CF samples. Could they also comment on what they 
observe regarding the link between gender and the expression of TLR8-AS1 and TLR8 mRNA (also 
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located on chromosome X)? More in general, is there anything known about CF differently  affecting 
males and females? 
 
AUTHOR RESPONSE: We now mention a gender link with respect to XIST and TLT8/TLR8-AS1 and 
cite our previous work investigating gender differences in CF as follows:  
‘Gender dichotomy is recognised in chronic inflammatory lung diseases such as CF, chronic 
obstructive pulmonary disease (COPD) and asthma.  Females with CF have poorer lung function, 
higher mortality, earlier colonisation with Pseudomonas aeruginosa, and deteriorate with 
Burkholderia earlier than their male counterparts (Block et al., 2006, Corey et al., 1997, Demko et 
al., 1995, Jackson et al., 2011a, Jackson et al., 2011b, Rosenfeld et al., 1997).  Recent work has 
focused on the role of steroid sex hormones such as estrogens in this ‘gender gap’ (Chotirmall et 
al. 2010 and 2012a) and has been reviewed elsewhere (Chotirmall et al., 2012b, Saint-Criq and 
Harvey, 2013, Sweezey and Ratjen, 2013).  The role of either genes or lncRNAs located on the sex 
chromosomes has to our knowledge not yet been examined and would provide additional insight 
into this gender gap.  Some of the transcripts discussed in this study for example, such as XIST, 
TLR8 and TLR8-AS1 are located on the X chromosome, but their role in CF lung pathology has yet 
to be determined.’ 
 
Reviewer 2 
The authors assayed the expression levels of about 30,000 lncRNAs in bronchial cells of 7 healthy 
and 6 CF patients and found about 1000 lncRNAs that were differentially expressed between the two 
groups as measured by a microarray. The same technique was used to identify diferentially 
expressed coding transcripts. 720 such transcripts were found. That the differences exist in the 
CF/healthy state is not that surprising. Nevertheless this work represents a novel step in the analysis 
of the CF phenotype.  
Overall the data suggest that the bronchial cells of CF vs nonCF patients differ mainly in their 
inflammatory status. That is not a novel observation although showing that lncRNAs are involved is 
novel. What is troubling that the validation of the microarray results by qRT-PCR was very weak and 
therefore it is impossible even to speculate if there is clinical relevance to these findings. This 
weakness is compounded by the fact that subject groups were small, the healthy group was 
significantly older than the CF group and that there is no clear data on the bacterial infection status 
of CF patients. One then is unable to conclude if the lncRNA changed due to infection or because is it 
inherent to the disease. 
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AUTHOR RESPONSE: In the intervening time-period we have been able to collect additional patient 
samples for further validation studies (n-7 CF, n=9 non-CF) and now present more robust data in 
Figures 2-4.  
 
Unfortunately we are unable to access an age-matched control group, and would not be in a 
position to repeat the lncRNA array studies.  
 
We now include the infection status and FEV1 % predicted of the CF subjects in Table 2 (below) and 
comment on the possible effects of infection and CFTR genotype in the discussion as follows: ‘It 
remains to be determined what direct contribution mutant CFTR makes to an altered CF 
transcriptome, and it is highly likely that other factors such as infection and inflammation are 
major contributors to this altered expression of both lncRNAs and protein coding transcripts.’ 
 
Table 2.  FEV1 % predicted and colonisation status of the CF patient sample data. 
Patient 
ID 
FEV1 
(%Predicted) 
Pseudomonas 
aeruginosa 
Staphylococcus 
aureus 
Aspergillus 
spp. 
Candida 
spp. 
Other 
CF_x 87% Positive Positive Positive Negative Negative 
Cf_y 29% Positive Negative Positive Positive Negative 
CF_z 54% Positive Negative Negative Negative Negative 
CFa 36% Negative Negative Positive Positive 
Stenotrophomonas 
maltophilia 
CFb 82% Negative Positive Positive Positive Negative 
CFc 66% Positive Negative Positive Positive Negative 
CFd 29% Positive Positive Negative Positive Negative 
CFe 83% Negative Positive Negative Negative Negative 
CFf 27% Negative Positive Negative Positive Negative 
CFg 22% Positive Positive Negative Positive Negative 
Legend: FEV1: Forced expiratory volume in one second 
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Abstract 
Long non-coding RNAs (lncRNAs) have emerged recently as key regulatory molecules with 
diverse roles at almost every level of the regulation of gene expression. The roles of these 
RNAs in the pathogenesis of cystic fibrosis (CF); a lethal multisystem, autosomal recessive 
disorder have yet to be explored.  Our aim was to examine the expression profile of lncRNA, 
in the airway epithelium of people with CF.  We examined the expression of 30,586 lncRNAs 
by microarray (Human LncRNA Array v3.0, Arraystar, Inc), in vivo in bronchial cells isolated 
from endobronchial brushings obtained from CF and non-CF individuals.  In total, we 
identified 1,063 lncRNAs with differential expression between CF and non-CF individuals 
(fold change≥3, p≤0.001).  The microarray also contained probes for ~26,109 protein coding 
transcripts, of which 720 were differentially expressed between CF and non-CF brush 
samples (fold change≥3, p≤0.001).  Confirmation of a selection of differentially expressed 
coding mRNA and lncRNA transcripts such as XIST and TLR8 was achieved using qRT-
PCR. Gene ontology bioinformatics analysis highlighted that many processes over-
represented in the CF bronchial epithelium are related to inflammation.  These data show a 
significantly altered lncRNA and mRNA expression profile in CF bronchial cells in vivo.  
Dysregulation of some of these lncRNAs may play important roles in the chronic infection 
and inflammation that exists in the lungs of people with CF.   
 
Keywords: Cystic fibrosis, bronchial epithelial cells, lncRNA, XIST, TLR8 
Acknowledgements:  
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Introduction 
Cystic fibrosis (CF) is a lethal multisystem, autosomal recessive disorder, affecting 
many organs. Its pulmonary manifestations are responsible for the associated high morbidity 
and mortality. CF is characterised by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, of which over 1900 mutations have been identified to 
date. A deletion of phenylalanine at position 508 of the CFTR protein (p.Phe508del) is the 
most frequent mutation, and accounts for approximately 70% of the alleles in CF worldwide 
(Sheridan et al., 2011), and 90.2% of alleles in the Republic of Ireland (Cystic Fibrosis 
Registry of Ireland, 2012). The CFTR gene encodes an ATP-regulated chloride channel and 
is present within the apical surface of epithelial cells. The development of chronic 
inflammatory lung disease is typically the primary manifestation in people with CF, with 
additional disease in other organ systems including pancreatic insufficiency, sweat 
electrolyte imbalance and male infertility (Sheridan et al., 2011). Some of the major 
determinants of CF lung disease include a decreased airway surface liquid volume, 
increased mucus viscosity, chronic microbial colonisation, an impaired protease-antiprotease 
balance and increased pulmonary inflammation. Bronchial epithelial cells with their array of 
pattern recognition receptors, such as the Toll-like receptors (TLRs), are key contributors to 
the airway inflammation evident in the CF lung. When stimulated with their cognate agonists, 
these cells have been shown to promote pro-inflammatory gene expression, within the 
context of CF (Greene et al., 2005, Carroll et al., 2005). Although advances in recent years 
have improved treatment and lengthened the median survival of people with CF (Dodge et 
al., 2007), there is still no effective cure. Therefore, determining the expression and function 
of long non-coding RNAs (lncRNAs) in CF will illuminate regulatory mechanisms controlling 
changes in gene expression and could direct the development of future therapeutic 
approaches.  
Non-coding RNAs have emerged recently as key regulatory molecules with diverse 
roles in fundamental biological processes. These RNA transcripts can be divided into two 
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classes based on length; lncRNAs (>200 nt), or short ncRNAs (<200 nt) such as microRNAs, 
small nucleolar RNAs and piwi-interacting RNAs. lncRNAs have many diverse functions. 
They have the ability to bind to RNA, DNA and protein.  They can be used in cells as an 
indicator or signal of transcriptional activity. They can act as decoys by binding to RNA or 
protein and titrating these away from other molecules; they can act as guides to direct 
localisation of ribonucleoprotein complexes; and they can act as scaffolds and structural 
platforms for nuclear processes. Aberrant expression of lncRNAs have been associated with 
various human conditions, including those as diverse as cancers (Yu et al., 2012), myocardial 
infarction (Ishii et al., 2006a) and Alzheimer‟s disease (Faghihi et al., 2008). lncRNAs have been 
shown to be involved in the regulation of gene expression at almost every level, from nuclear 
epigenetic modifications to cytoplasmic mRNA translation.  Our group was the first to examine 
the microRNA expression profile of the CF airway epithelium (Oglesby et al., 2010).  Performed 
on endobronchial brushings from people with and without CF, microRNA profiling studies 
identified various microRNAs that had altered expression in CF. Our group also identified that 
three of these microRNAs with increased expression in vivo (miR-145, miR-223, and miR-494) 
correlate with decreased Phe508del CFTR expression and regulate its expression (Oglesby et 
al., 2013) . What remains to be seen is whether there exists an altered lncRNA profile in the CF 
airway epithelium.   
In this study, we have profiled the expression of lncRNA and mRNA in airway 
epithelial cells obtained from endobronchial brushings from people with and without CF.  We 
also evaluated differentially expressed lncRNAs in independent patient samples.  Our results 
demonstrate an altered expression profile of lncRNAs in cystic fibrosis bronchial epithelial 
cells. 
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Materials and Methods 
Study populations and bronchial brush sampling.  
Twenty-two individuals were recruited into this study; ten had CF (confirmed by 
sweat testing and/or genotyping) and twelve were non-CF controls, with a mean age of 22.4 
± 4.9 y and 37.2 ± 15.6 y, respectively (Table 1).  Forced expiratory volume in one second 
(FEV1) and colonisation status of CF individuals are shown in table 2. 
All participants were undergoing diagnostic and/or therapeutic fibre-optic flexible 
bronchoscopy as part of routine care. Non-CF control individuals were undergoing 
exploratory bronchoscopy in the investigation into idiopathic pulmonary disease.  Fully 
informed consent was obtained before the procedure, and appropriate approval was 
obtained from our institutional review board. After completion of the bronchoscopy and 
before the withdrawal of the bronchoscope, an area 2 cm distal to the carina (medially 
located) in either the right or left main bronchus was selected and washed twice with 10 ml 
sterile 0.9% NaCl. Next, a sterile 10 x 1.2-mm bronchial brush (Olympus Medical Systems, 
Tokyo, Japan) was inserted through the appropriate port on the bronchoscope and the 
chosen area sampled with two consecutive brushes by scraping the area gently. The brush 
was withdrawn and immediately placed in 5 ml RPMI+Glutamax supplemented with 10% 
foetal calf serum and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA).  
 
Isolation of RNA.  
Brushes were gently agitated to dislodge cells into the media, which was centrifuged 
at 300 × g for 5 minutes, and cell pellets were resuspended in Tri Reagent (Sigma-Aldrich) 
before RNA extraction as per manufacturer‟s protocol.  The quality and the concentration of 
the RNA samples were monitored at absorbance ratios of A260/A280 and A260/A230 using a 
NanoDrop 8000 spectrophotometer. 
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RNA labelling and array hybridisation.  
Expression profiling studies were performed on RNA from three individuals with CF 
(one male and two female) and three non-CF controls (one male and two female) by 
Arraystar, Inc. (Rockville, MD, USA). Total RNA from each sample was quantified by the 
NanoDrop ND-1000 and RNA integrity was assessed by standard denaturing agarose gel 
electrophoresis. For microarray analysis an Agilent array platform was employed. mRNA 
was purified from total RNA after removal of rRNA using the mRNA-ONLY™ Eukaryotic 
mRNA Isolation Kit (Epicentre Biotechnologies, Madison, WI, USA). Each sample was 
amplified and transcribed into fluorescent cRNA along the entire length of the transcripts 
without 3‟ bias utilizing a random priming method. The concentration and specific activity of 
the labeled cRNAs (pmol Cy3/μg cRNA) were measured by NanoDrop ND-1000, 1 μg of 
each labeled cRNA was fragmented by adding 5 μl 10x blocking agent and 1 μl of 25x 
fragmentation buffer, heated to 60 °C for 30 min, and diluted with  25 μl 2x GE hybridisation 
buffer. 50 μl of hybridisation solution was dispensed into the gasket slide and assembled to 
the Human LncRNA Array v3.0 slide (8 x 60K, Arraystar). The slides were incubated for 17 
hours at 65°C in an Agilent hybridisation oven then washed, fixed and scanned using the 
Agilent DNA Microarray Scanner (part number G2505C). Approximately 30,586 lncRNAs 
and 26,109 coding transcripts collected from the most authoritative databases, such as 
RefSeq (release 55), UCSC Human (GRCh37/hg19), GENCODE 13, and lncRNAdb (2.0) 
were detected using microarray.  Microarray data from this study has been archived to the 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo, accession number 
GSE55146). 
 
Data analysis.  
Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired 
array images. Quantile normalization was performed using Expander and subsequent data 
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processing was performed using the GeneSpring GX v12.0 software package (Agilent 
Technologies). Quantile normalisation of the raw data was carried out. This is a 
transformation to make the distribution of probe intensities identical for all arrays performed. 
Data was filtered to remove transcripts with unreliable expression measurements (transcripts 
that at least 1 out of 6 samples have flags in „present‟ or „marginal‟ were chosen for further 
analysis), lncRNAs and mRNAs with expression above a set threshold were chosen for 
further analysis. Differentially expressed lncRNAs and mRNAs between two groups were 
identified through volcano plot filtering and hierarchical clustering was performed to show the 
distinguishable lncRNA and mRNA expression patterns among samples. 
 
LncRNA classification and pathway analysis.  
Differentially expressed lncRNAs were assigned to different subgroups to aid in the 
identification of any putative functional relationships between lncRNAs and their associated 
protein-coding genes.  Subgroups included lncRNAs with enhancer-like functions, long 
intergenic RNAs (lincRNA), human homeobox transcription factors (HOX) cluster profiling, 
lincRNAs nearby coding genes, and enhancer lncRNAs nearby coding genes. Our 
microarray enabled the expression analysis of ~26,109 protein coding transcripts, broadly 
covering the ~20,600 protein coding genes estimated by GENCODE (Harrow et al., 2012).  
Pathway analysis and gene ontology (GO) analysis were applied to determine the potential 
roles that the differentially expressed mRNAs played in biological pathways or GO terms.  
The GO project provides a controlled vocabulary to describe gene and gene product 
attributes in any organism (http://www.geneontology.org). The ontology covers three 
domains: biological process, cellular component and molecular function. Fisher‟s exact test 
is used to find if there is more overlap between the differentially expressed gene list and the 
GO annotation list (Ashburner et al., 2000) than would be expected by chance. The p-value 
denotes the significance of GO terms enrichment in the differentially expressed gene list. 
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Validation of microarray data by quantitative real-time reverse transcription 
polymerase chain reaction.  
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to confirm the 
expression pattern of selected lncRNAs and mRNAs in additional samples.  These 
validations could not be performed on the original samples due to a lack of material. cDNA 
was synthesized from 1 μg total RNA using the Quantitect Reverse Transcription kit 
(Qiagen, Valencia, CA, USA). The resulting cDNA was template for quantitative real-time 
PCR. Oligonucleotide primers (Table 3) were synthesized (MWG Biotech) and quantitative 
PCR reactions performed in 20 μl containing 2 μl template cDNA, 2× SYBR Green master 
mix (Roche, Basel, Switzerland), and 10 pmol of each primer. Amplification was performed 
using the LightCycler 480 PCR system (Roche) with the expression of target genes relative 
to the reference genes GAPDH and ACTB, determined using the 2(−ΔΔCt) method (Livak and 
Schmittgen, 2001). Technical replicates were only performed on reference gene PCR due to 
scarcity of sample.  All qRT-PCR experiments included no-template controls.  PCR product 
was examined by agarose gel electrophoresis using 2% (w/v) LE agarose (Seakem) stained 
with ethidium bromide. 
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Results 
lncRNA microarray profiling of bronchial brushings 
Microarray profiling of 30,586 lncRNAs (Figure 1A and C) was carried out using 
Arraystar Human LncRNA Microarray v3.0 by the service provider ArrayStar, Inc (Rockville, 
MD, USA).  In total, 1063 lncRNAs were identified with differential expression between 
samples from people with and without CF (fold change ≥ 3, p ≤0.001; for a list of differentially 
expressed lncRNAs see Supplementary Table 1).  The majority of lncRNAs with differential 
expression in this study were intergenic (~58%), within introns of protein coding genes 
(~18%), or antisense to protein coding loci (~12%) with the remainder representing 
overlapping transcripts from exons or introns in both sense and antisense directions.  A 
selection of these differentially expressed lncRNA transcripts that were selected for further 
studies are shown in Figure 1B and listed in Table 4. 
 
Real-time quantitative PCR validation 
To validate the microarray profiling expression data the expression of XIST, MALAT1 
and HOTAIR were examined.  This was achieved by performing real-time quantitative PCR 
(qRT-PCR) analysis on additional independent bronchial brushing samples from people with 
and without CF. A similar up-regulation was observed in both microarray and qRT-PCR 
samples for the XIST lncRNA transcript (Figure 2).   
The microarray indicated that MALAT1 and HOTAIR are down-regulated in CF 
versus non-CF bronchial brushings (Figure 3). Validation by qRT-PCR in additional 
independent clinical samples failed to confirm this expression pattern for MALAT1 and 
HOTAIR.   
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mRNA profiling of bronchial brushings by microarray 
The microarray also contained probes for ~26,109 protein coding transcripts, of 
which 720 were differentially expressed between CF and non-CF bronchial brush samples 
(Figure 1D; fold change ≥ 3, p ≤0.001; for a list of differentially expressed mRNAs see 
Supplementary Table 2).  Gene ontology (GO) analysis is a functional analysis associating 
differentially expressed mRNAs with GO categories. The GO categories are derived from the 
Gene Ontology Project (http://www.geneontology.org), which comprise three structured 
networks of defined terms that describe gene product attributes. GO analysis of the 
differentially expressed mRNAs in this study identified numerous biological processes with 
significantly altered expression of gene products involved.  Many of these processes which 
are up-regulated in CF bronchial brushings are related to inflammation and Toll-like receptor 
signaling (Table 5).  In contrast, many of these processes which are down-regulated in CF 
bronchial brushings are involved in regulation of metabolism (Table 6). 
 
Expression of TLR8 and its antisense lncRNA TLR8-AS1 in the CF airway epithelium 
The expression of many lncRNAs and coding mRNAs are linked. For instance, many 
are transcribed from divergent transcription at the promoters of protein coding genes.  
Interestingly, the microarray data indicated that Toll-like receptor 8 (TLR8) mRNA was up-
regulated in CF samples, whereas its natural antisense lncRNA transcript, encoded on the 
opposite strand; TLR8-AS1, was down-regulated in the same samples (Figure 4).  TLR8 
mRNA expression was confirmed to be up-regulated in the CF group.  TLR8-AS1 lncRNA 
expression is low and was identified in three out of nine additional independent non-CF 
samples and only one of seven independent CF brushing samples, as determined by PCR 
followed by agarose gel electrophoresis (data not shown).   
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Discussion 
Bronchial epithelial cells contribute significantly to the airway inflammation evident in 
the CF lung by responding to host- and pathogen-derived agonists such as neutrophil 
elastase and Pseudomonas aeruginosa lipopolysaccharide (LPS).  These can signal via 
TLRs to augment interleukin-8 (IL-8) expression, leading to neutrophil dominated 
inflammation (Greene et al., 2005, Cosgrove et al., 2011, Chotirmall et al., 2010).  Here we 
demonstrate that there is a significantly altered lncRNA and mRNA expression profile in CF 
bronchial cells in vivo.  We have identified 1,063 lncRNA, and 720 protein coding transcripts 
with differential expression between CF and non-CF bronchial epithelial cells and we 
confirmed a selection of these differentially expressed transcripts by qRT-PCR.  Therefore, 
the data shown here provides a comprehensive profile of the lncRNA and coding transcript 
expression in the bronchial epithelium of people with CF. 
As protein-coding genes account for only ~ 1.2% of the human genome (Consortium, 
2004), it is becoming progressively more apparent that the majority of the genome is 
transcribed into non-protein-coding RNAs (Johnsson et al., 2014).  lncRNAs have been 
shown to be involved in the regulation of gene expression, via many mechanisms.  
Thousands of lncRNAs have been identified; most of whose functions remain unknown.  
Recent studies have revealed numerous evolutionarily conserved lncRNAs. Athough the 
promoters of lncRNAs are mostly well conserved (Johnsson et al., 2014, Derrien et al., 2012, 
Pang et al., 2006), these lncRNA transcripts tend to be less well conserved than other 
protein-coding transcripts (Guttman et al., 2009, Ponjavic et al., 2007).  Nonetheless, they 
are largely functionally conserved (Johnsson et al., 2014).   
Only a handful of studies to-date have examined lncRNA expression in lung disease.  
Most recent studies have examined the expression of lncRNA in various non small cell lung 
cancers  (Yang et al., 2013, Lu et al., 2013, Liu et al., 2013).  To our knowledge, this is the 
first report on the expression of lncRNAs in the CF bronchial epithelium.   
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Although there was a disparity between lncRNA expression levels as determined by 
microarray versus qRT-PCR there are a number of potential reasons; (i) There was a large 
variation in the expression of some lncRNAs in the independent qRT-PCR assayed samples.  
Many factors can contribute to this heterogeneity including age, gender, pulmonary function, 
microbial colonisation status and use of medications; (ii) Profiling was based on a 
hybridisation probe-based method whereas the validation studies used an alternative qRT-
PCR approach.  As regards qRT-PCR, „traditional‟ reference genes such as GAPDH and 
ACTB have previously been found to be unsuitable for normalisation of mRNA levels in the 
airways of asthmatics (Glare et al., 2002), for gene expression studies employing alveolar 
macrophages from people with chronic obstructive pulmonary disease (Ishii et al., 2006b) 
and in bronchoalveolar cells from patients with other pulmonary diseases (Kriegova et al., 
2008). A study to determine the reference genes with the most stable mRNA expression in 
bronchoalveolar cells from horses with inflammatory airway disease identified an optimal 
four gene reference panel (Beekman et al., 2011).  Due to a lack of biological material at our 
disposal, we utilised a two gene normalisation approach using GAPDH and ACTB in 
combination, having validated that there is no significant difference in expression of either 
gene between bronchial epithelial cells subjects from CF or control groups; (iii) The sample 
sizes used were small; thus not allowing for high statistical power.  This is a challenge given 
that these are rare samples obtained from a highly invasive clinical procedure.  Therefore, 
although the selected lncRNAs were not all validated, this is not unexpected; however those 
that were validated may have clinical importance, and are worth further study.   
One of the confirmed differentially expressed lncRNAs described here, X inactive 
specific transcript (XIST) plays a central role in the process of X chromosome inactivation 
(XCI).  This is the process whereby one of the two X chromosomes in females is inactivated, 
to equal male dosage of X chromosome gene products.  One of the few well documented 
lncRNAs, the 16-19 kb XIST RNA is transcribed from the inactive X chromosome, spreads 
over and coats (what will become) the inactive X chromosome in cis (Engreitz et al., 2013, 
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Simon et al., 2013).  XIST physically associates with and brings the Polycomb repressive 
complex 2 (PRC2), which is involved in the trimethylation of histone H3 lysine 27 
(H3K27me3) of this chromosome, and ultimately leads to its inactivation (Rinn and Chang, 
2012).  Why XIST is up-regulated in CF bronchial cells remains unclear.  Interestingly it was 
not only increased in CF females, but it also was expressed in CF males.  Normally, as 
males only have one X chromosome, the only period in which this lncRNA is expressed is in 
the germline, in the XCI of diploid primary spermatocytes during spermatogenesis.  
Therefore, XIST transcripts are not expected to be present in males.  Up-regulation of XIST 
expression has been observed in males with testicular germ cell tumours (Looijenga et al., 
1997), and those with Klinefelter syndrome (47XXY) (Kleinheinz and Schulze, 1994).  
However, this is likely to be due to gain of additional X chromosomes rather than other 
epigenetic changes.  This increased expression of XIST in the CF lung raises many 
questions. XIST is currently believed to function only in cis, however this may not be the 
case, and it may affect gene expression on other chromosomes. 
Gender dichotomy is recognised in chronic inflammatory lung diseases such as CF, 
chronic obstructive pulmonary disease (COPD) and asthma.  Females with CF have poorer 
lung function, higher mortality, earlier colonisation with Pseudomonas aeruginosa, and 
deteriorate with Burkholderia earlier than their male counterparts (Block et al., 2006, Corey 
et al., 1997, Rosenfeld et al., 1997, Demko et al., 1995, Jackson et al., 2011a, Jackson et 
al., 2011b).  Recent work has focused on the role of steroid sex hormones such as 
estrogens in this „gender gap‟ (Chotirmall et al., 2010, Chotirmall et al., 2012a) and has been 
reviewed elsewhere (Chotirmall et al., 2012b, Saint-Criq and Harvey, 2013, Sweezey and 
Ratjen, 2013).  The role of either genes or lncRNAs located on the sex chromosomes has to 
our knowledge not yet been examined and would provide additional insight into this gender 
gap.  Some of the transcripts discussed in this study for example, such as XIST, TLR8 and 
TLR8-AS1 are located on the X chromosome, but their role in CF lung pathology has yet to 
be determined. 
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The TLRs are a family of pattern recognition receptors involved in the detection of a 
diverse array of microbial ligands, each being involved in sensing different microbial 
products.  Activated TLRs transduce intracellular signals to regulate the expression of pro-
inflammatory genes.  TLR8 expression was confirmed to be increased in this study in the CF 
lung.  TLR8 recognises single stranded RNA from viruses and is involved in the detection of 
bacterial RNA (Karikó et al., 2005, Cervantes et al., 2011).  In the context of bronchial 
epithelial cells, stimulation of TLR8 can induce interferon and IL-8 expression in bronchial 
epithelial cells from both asthmatics and non-asthmatics (Sykes et al., 2013).  Here, 
microarray profiling data suggested that the TLR8 natural antisense lncRNA, the 1349 bp 
TLR8-AS1 transcript, is down-regulated in CF bronchial epithelium. PCR analysis detected 
low level expression in three out of nine non-CF control and in only one out of seven CF 
bronchial epithelial samples.  This may imply a partial loss of regulation of TLR8 expression, 
and although very little is known about the functions of this lncRNA, this transcript may hold 
relevance in the context of viral exacerbations of CF. 
The microarray based profiling identified more than 700 coding RNA transcripts with 
differential expression in the CF bronchial epithelium.  Gene ontology analysis indicated that 
pathways regulating growth and metabolic processes were down-regulated in the CF lung.  
Conversely, inflammatory processes such as TLR signalling pathways were up-regulated.  
These results are concordant with the known inflammatory nature of the CF lung and show a 
similar profile to that found by others (Ogilvie et al., 2011).  For example, target of Myb1 
(TOM1) is a negative regulator of TLR2/4 signalling, that is significantly up-regulated in CF 
bronchial epithelial cells (Oglesby et al., 2010); TOM1 mRNA expression was also increased 
in the CF samples tested in this study (data not shown).  Other studies have profiled mRNA 
expression within the context of CF.  At least three studies have profiled mRNA expression 
in the CF nasal epithelium (Ogilvie et al., 2011, Wright et al., 2006, Clarke et al., 2013).  
Worth noting is the fact that all of these studies identified different groups of differentially 
expressed genes, with few consistently altered in cystic fibrosis.  Differences between 
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studies may be partly explained by different experimental procedures employed.  These 
differences include genotype of the cells used, statistical or normalisation approaches and 
tissue type; such as bronchial and nasal brushings (Ogilvie et al., 2011, Wright et al., 2006, 
Clarke et al., 2013), isogenic bronchial cells (Virella-Lowell et al., 2000), primary tracheal 
and bronchial cell cultures (Zabner et al., 2005) and foetal tracheal cells (Verhaeghe et al., 
2007).  It remains to be determined what direct contribution mutant CFTR makes to an 
altered CF transcriptome, and it is highly likely that other factors such as infection and 
inflammation are major contributors to this altered expression of both lncRNAs and protein 
coding transcripts. 
 
Conclusion 
We illustrate a significantly altered lncRNA and mRNA expression profile in CF 
bronchial cells in vivo.  Dysregulation of some of these lncRNAs may play important roles in 
the chronic infection and inflammation that exists in the lungs of people with CF.  What 
remains to be determined is whether these changes are indirectly due to the p.Phe508del 
genotype, or infection and inflammatory states, or a combination of these factors.  Further 
mechanistic studies in this area using clinically relevant samples will help to elucidate the 
exact roles of many of these lncRNA in the chronic infection and inflammation associated 
with CF. 
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Tables 
Table 1.  Endobronchial brushing patient sample data. 
Patient Status Gender CFTR Genotype 
Age 
(Years) 
Sample 
use 
C_01 Non-CF F N/A 20 Array 
C_02 Non-CF M N/A 46 Array 
C_03 Non-CF F N/A 37 Array 
C001 Non-CF M N/A 43 qRT-PCR 
C002 Non-CF F N/A 42 qRT-PCR 
C003 Non-CF M N/A 39 qRT-PCR 
C004 Non-CF M N/A 76 qRT-PCR 
C005 Non-CF F N/A 19 qRT-PCR 
C006 Non-CF M N/A 37 qRT-PCR 
C007 Non-CF M N/A 18 qRT-PCR 
C008 Non-CF F N/A 32 qRT-PCR 
C009 Non-CF M N/A 37 qRT-PCR 
      
CF_x CF M p.Phe508del/p.Phe508del 18 Array 
Cf_y CF F p.Phe508del/p.Phe508del 22 Array 
CF_z CF F p.Phe508del/p.Phe508del 18 Array 
CFa CF F p.Phe508del/p.Phe508del 18 qRT-PCR 
CFb CF M p.Phe508del/p.Glu60X 20 qRT-PCR 
CFc CF F p.Phe508del/unknown 28 qRT-PCR 
CFd CF M p.Phe508del/p.Phe508del 29 qRT-PCR 
Cfe CF F p.Phe508del/p.Arg117His 29 qRT-PCR 
CFf CF F p.Phe508del/p.Phe508del 17 qRT-PCR 
CFg CF F p.Phe508del/p.Phe508del 25 qRT-PCR 
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Table 2.  FEV1 and colonisation status of the CF patient sample data. 
Patient 
ID 
FEV1 
(%Predicted) 
Pseudomonas 
aeruginosa 
Staphylococcus 
aureus 
Aspergillus 
spp. 
Candida 
spp. 
CF_x 87% Positive Positive Positive Negative 
Cf_y 29% Positive Negative Positive Positive 
CF_z 54% Positive Negative Negative Negative 
CFa 36% Negative Negative Positive Positive 
CFb 82% Negative Positive Positive Positive 
CFc 66% Positive Negative Positive Positive 
CFd 29% Positive Positive Negative Positive 
CFe 83% Negative Positive Negative Negative 
CFf 27% Negative Positive Negative Positive 
CFg 22% Positive Positive Negative Positive 
Legend: FEV1: Forced expiratory volume in one second 
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Table 3.  Details of primer pairs used in analysis of lncRNA and mRNA expression by 
qRT-PCR. 
 
lncRNA/mRNA Forward  Primer Reverse Primer 
Annealing 
Temp (°C) 
Product 
Size 
(bp) 
GAPDH 5‟- ATGTTCCTTCAGTCGTCAATGC -3‟ 5‟-AGTCCTTCCACGATACCAAAGT-3‟ 57 113 
XIST 5‟-GTCAGGAGAAAGAAGTGGAGGG-3‟ 5‟-ACAGAGGAATGGAGGGAGGTT-3‟ 56 193 
BACT 5‟-GGACTTCGAGCAAGAGATGG-3‟ 5‟-AGGAAGGAAGGCTGGAAGAG-3‟ 56 138 
MALAT1 5'-AAGTTCCGGGGGTTTTGTGA-3' 
5'-ACAACTCGCATCACCGGAAT-3' 
56 263 
HOTAIR 
5'-GGTAGAAAAAGCAACCACGAAGC-3' 5'-ACATAAACCTCTGTCTGTGAGTGCC-3' 
56 170 
TLR8 
5‟-ATGTTCCTTCAGTCGTATGC-3‟ 5‟- TTGCTGCACTCTGCAATAACT -3‟ 
55 
143 
TLR8-AS1 
5‟-AGACAGCACCGACTTCACAC-3‟ 5‟-TATGTGGTACTTCGCGGCAG-3‟ 
57 174 
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Table 4. lncRNAs differentially expressed in CF vs. non-CF bronchial brushings 
determined by microarray (Arraystar Human LncRNA Microarray v3.0) selected for 
validation studies. 
P-value 
Fold 
change 
(absolute) 
Regulation GeneSymbol 
RNA 
length 
Chromosome Strand Relationship 
0.00000 10.35 up XIST 724 chrX - intergenic 
0.0021456 5.95449 down HOTAIR 2337 chr12 - intergenic 
0.0080544 4.617822 down MALAT1 8708 chr11 + intergenic 
0.003241 2.1243474 down TLR8-AS1 1660 chrX - intronic antisense 
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Table 5. Gene ontology analysis: biological processes up-regulated in CF bronchial 
brushings. 
GO.ID Term Count P value 
Enrichment 
Score 
GO:0044267 cellular protein metabolic process 421 0.00009 4.053 
GO:0002755 MyD88-dependent Toll-like receptor signalling pathway 21 0.00018 3.735 
GO:0009987 cellular process 1635 0.00027 3.566 
GO:0002224 Toll-like receptor signalling pathway 24 0.00030 3.522 
GO:0002758 innate immune response-activating signal transduction 25 0.00040 3.397 
GO:0055085 transmembrane transport 149 0.00041 3.385 
GO:0002218 activation of innate immune response 25 0.00056 3.253 
GO:0002221 pattern recognition receptor signalling pathway 24 0.00060 3.221 
GO:0043412 macromolecule modification 328 0.00065 3.190 
GO:0006464 protein modification process 316 0.00078 3.110 
GO:0002756 
MyD88-independent Toll-like receptor signalling 
pathway 
18 0.00102 2.991 
Legend: GO.ID: Gene Ontology ID; Term: The name of Gene Ontology terms; Count: number of 
genes involved; P value: P-value as calculated by Fisher’s exact test; Enrichment Score:-log10(P-
value). 
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Table 6. Gene ontology analysis: biological processes down-regulated in CF bronchial 
brushings. 
GO.ID Term Count P value Enrichment Score 
GO:0045926 negative regulation of growth 29 0.00003 4.595 
GO:0050789 regulation of biological process 748 0.00006 4.206 
GO:0040008 regulation of growth 59 0.00007 4.133 
GO:0065007 biological regulation 790 0.00007 4.128 
GO:0050794 regulation of cellular process 712 0.00010 4.001 
GO:0010885 regulation of cholesterol storage 6 0.00032 3.499 
GO:0006793 phosphorus metabolic process 156 0.00035 3.458 
GO:0006796 phosphate metabolic process 156 0.00035 3.458 
GO:0010878 cholesterol storage 6 0.00054 3.264 
GO:0006468 protein phosphorylation 125 0.00055 3.262 
GO:0007049 cell cycle 138 0.00061 3.216 
GO:0007169 
transmembrane receptor protein tyrosine kinase 
signalling pathway 
73 0.00070 3.156 
GO:0045449 regulation of transcription 300 0.00089 3.050 
Legend: GO.ID: Gene Ontology ID; Term: The name of Gene Ontology terms; Count: number of 
genes involved; P value: P-value as calculated by Fisher’s exact test; Enrichment Score:-log10(P-
value). 
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Figure legends. 
Figure 1. lncRNA and mRNA microarray expression data from bronchial brushings of people 
with CF (CFx,CFy,CFz) and people without CF (C01,C02,C03).  Microarray data were log-
transformed and normalised using quantile normalisation. After filtering to remove unreliable 
transcripts, the remaining were statistically analysed to identify lncRNAs and mRNAs with 
significant differential expression.  (A) The result of hierarchical clustering dendrogram 
shows a distinguishable lncRNA expression profile among samples.  (B) Heat map depicting 
a selection of up-regulated (XIST) and down-regulated (MALAT1, RP11_59E19.4, HOTAIR, 
TLR8-AS1) lncRNAs in the CF versus non-CF bronchial brushings. “Red” indicates high 
relative expression, and “green” indicates low relative expression. (C) lncRNA and (D) 
mRNA volcano plots of CF versus non-CF bronchial epithelial cells (fold-change ≥ 2.0 and 
P < 0.05). Each square represents a different transcript. Transcripts are distributed 
according to statistical significance (y-axis) and magnitude of change (log2 ratio CF:non-CF) 
(x-axis). Red squares represent genes that pass the statistical and fold-change cut-offs.   
  
Figure 2.  Comparison between microarray and qRT-PCR data for quantification of XIST 
expression in bronchial brushings from people with and without CF.  XIST transcript levels 
were quantified by lncRNA microarray (Arraystar Human LncRNA Microarray v3.0, CF vs. 
non-CF, n=3 each) or real-time PCR (CF, n=7 vs. non-CF, n=9, one technical replicate 
each), each normalised to internal controls (GAPDH and ACTB, two technical replicates 
each).  Results are presented as log2 fold change ± SEM relative to the expression in non-
CF samples.  Positive values indicate lncRNAs up-regulated in CF. 
 
Figure 3.  Comparison between microarray and qRT-PCR data for quantification of lncRNA 
expression in bronchial brushings from people with and without CF. HOTAIR and MALAT1 
transcript levels were quantified by lncRNA microarray (Arraystar Human LncRNA 
32 
 
Microarray v3.0, CF vs. non-CF, n=3 each), or real-time PCR (CF, n=7 vs. non-CF, n=9, one 
technical replicate each), each normalised to internal controls (GAPDH and ACTB, two 
technical replicates each).  Results are presented as log2 fold change ± SEM relative to the 
expression in non-CF samples.  Positive or negative values indicate lncRNAs up-regulated 
or down-regulated in CF, respectively. 
 
Figure 4.  Evaluation of TLR8 coding RNA and TLR8-AS1 lncRNA expression by microarray 
and qRT-PCR in bronchial brushings from people with and without CF.  The level of TLR8 
and TLR8-AS1 transcripts were quantified by lncRNA microarray (Arraystar Human LncRNA 
Microarray v3.0, CF vs. non-CF, n=3 each).  The levels of TLR8 were quantified and 
confirmed in additional samples by real-time PCR (CF, n=7 vs. non-CF, n=9, one technical 
replicate each), each normalised to internal controls (GAPDH and ACTB, two technical 
replicates each).  Results are presented as log2 fold change ± SEM relative to the 
expression in non-CF samples. Positive or negative values indicate transcripts up-regulated 
or down-regulated in CF, respectively. 
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Figure 2. 
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Figure 4. 
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Supplementary Files
Click here to download Supplementary Files: Supplementary Table 1 lncRNA.xlsx
Supplementary Files
Click here to download Supplementary Files: Supplementary Table 2 mRNA.xlsx
